VYNE insider trading
NasdaqCM HealthcareYarrow Bioscience, Inc.: insider trade history from SEC Form 4 filings.
About Yarrow Bioscience, Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Company website: vynetherapeutics.com
VYNE insider activity at a glance
FilingIQ tracks 157 insider transactions for VYNE in filings since Sep 8, 2020. The most recent transaction is dated Jul 23, 2026.
Across the full history, 12 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VYNE insider trades is 59.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VYNE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for VYNE?
- FilingIQ tracks 157 Form 4 insider transactions for VYNE (Yarrow Bioscience, Inc.), covering filings from Sep 8, 2020 onwards. 4 of those are dated within the last 90 days.
- Are VYNE insiders net buyers or net sellers?
- Across the full Form 4 history for VYNE, 12 transactions (8%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VYNE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is VYNE in?
- Yarrow Bioscience, Inc. (VYNE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.53M.
Methodology & sources
Every VYNE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.